NOD/ShiLtJGpt-Prkdc^em26Cd52/Gpt

NOD-Scid|Strain NO.T001492

Knockout (KO)

Product Type:
Quantity: - +
Sex:
Age:
Genotype:

BASIC INFORMATION

Strain Name:	NOD/ShiLtJGpt-Prkdc^em26Cd52/Gpt
Strain Number:	T001492
Official Symbol:	Prkdc
Strain Strategy:	T001492.Prkdc Cas9-KO Strategy-EN.pdf T001492.Nod-scid strain info..pdf
Official Full Name:	protein kinase,DNA activated,catalytic polypeptide
Also Known As:	AI326420,AU019811,DNA-PKcs,DNAPDcs,DNAPK,DNPK1,DOXNPH,HYRC1,XRCC7,dxnph,p460,scid,slip
NCBI Number:	19090
MGI Number:	104779
Chromosome:	16
Deletion (size):	-52bp
Research Areas:	immunodeficiency,Other immunodeficient strains,Humanization of the immune system,Immunodeficiency
Strain Background:	[N000235] NOD/ShiLtJGpt
Modification Type:	Knockout (KO)
Inventory Status:	Live,Cryopreserved
Sale Status:	IF (Available for Distribution)
Health Status:	Specific pathogen free (SPF)
Health Report:	Please log in to view
Publications:	1. CRMP2 is a therapeutic target that suppresses the aggressiveness of breast cancer cells by stabilizing RECK. Oncogene (2020)2. Establishment and characterization of a novel ‘double‐hit’follicular lymphoma cell line, FL‐SJC. Journal of Cellular and Molecular Medicine (2020)3. TRIM32/USP11 balances ARID1A stability and the oncogenic/tumor-suppressive status of squamous cell carcinoma. Cell reports (2020)4. Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth. Signal transduction and targeted therapy (2020)5. lncRNA NR2F1‐AS1 promotes breast cancer angiogenesis through activating IGF‐1/IGF‐1R/ERK pathway. Journal of cellular and molecular medicine (2020)6. Discovery of 8, 9-seco-ent-Kaurane Diterpenoids as Potential Leads for the Treatment of Triple-Negative Breast Cancer. Journal of Medicinal Chemistry (2021)7. Targeting FAPα-expressing tumor-associated mesenchymal stromal cells inhibits triple-negative breast cancer pulmonary metastasis. Cancer Letters (2021)8. Genome-wide CRISPR-Cas9 screen identified KLF11 as a druggable suppressor for sarcoma cancer stem cells. Science advances (2021)9. miR-18a promotes glioblastoma development by down-regulating ALOXE3-mediated ferroptotic and anti-migration activities. Oncogenesis (2021)10. Alanine-Glyoxylate Aminotransferase Sustains Cancer Stemness Properties through the Upregulation of SOX2 and OCT4 in Hepatocellular Carcinoma Cells. Biomolecules (2022)11. Synergism of FAK and ROS1 inhibitors in the treatment of CDH1-deficient cancers mediated by FAK-YAP signaling. International Journal of Biological Sciences (2023)12. Inhibition of DPAGT1 suppresses HER2 shedding and trastuzumab resistance in human breast cancer. J Clin Invest (2023)13. Acute myeloid leukemia (AML)-derived mesenchymal stem cells induce chemoresistance and epithelial-mesenchymal transition-like program in AML through IL-6/JAK2/STAT3 signaling. Cancer Sci (2023)14. In vivo self-assembly and delivery of VEGFR2 siRNA-encapsulated small extracellular vesicles for lung metastatic osteosarcoma therapy. Cell Death Dis (2023)15. PERK reprograms hematopoietic progenitor cells to direct tumor-promoting myelopoiesis in the spleen. Journal of experimental medicine (2022)16. Characterization of human pluripotent stem cell differentiation by single-cell dual-omics analyses. Stem Cell Reports (2023)17. Cisplatin-activated ERbeta/DCAF8 positive feedback loop induces chemoresistance in non-small cell lung cancer via PTEN/Akt axis. Drug Resist Updat (2023)18. Gli1 marks a sentinel muscle stem cell population for muscle regeneration. Nat Commun (2023)19. Preclinical characterization of danatinib as a novel FLT3 inhibitor with excellent efficacy against resistant acute myeloid leukemia. Biomed Pharmacother (2023)20. TSTA3 overexpression promotes malignant characteristics in LUSC by regulating LAMP2-mediated autophagy and tumor microenvironment. Cancer Cell Int (2023)21. Establishment of a Spontaneous Liver Fibrosis Model in NOD/SCID Mice Induced by Natural Aging. Biology (Basel) (2023)22. Predictive Roles of ADAM17 in Patient Survival and Immune Cell Infiltration in Hepatocellular Carcinoma. Int J Mol Sci (2023)23. VEGFA/NRP-1/GAPVD1 axis promotes progression and cancer stemness of triple-negative breast cancer by enhancing tumor cell-macrophage crosstalk. Int J Biol Sci (2024)24. LncRNA LBX2-AS1 inhibits acute myeloid leukemia progression through miR-455-5p/MYLIP axis. Heliyon (2024)25. Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer. Autophagy (2024)26. PBRM1 loss is associated with increased sensitivity to MCL1 and CDK9 inhibition in clear cell renal cancer. Front Oncol (2024)27. LncRNA CHROMR/miR-27b-3p/MET axis promotes the proliferation, invasion and contributes to rituximab resistance in diffuse large B-cell lymphoma. J Biol Chem (2024)28. Diagnostic potential of NRG1 in benign nerve sheath tumors and its influence on the PI3K-Akt signaling and tumor immunity. Diagnostic Pathology (2024)29. HMGA2 alleviates ferroptosis by promoting GPX4 expression in pancreatic cancer cells. Cell Death Dis (2024)30. 17beta-Estradiol promotes metastasis in triple-negative breast cancer through the Calpain/YAP/beta-catenin signaling axis. PLoS One (2024)31. LncRNA CHROMR/miR-27b-3p/MET axis promotes the proliferation, invasion, and contributes to rituximab resistance in diffuse large B-cell lymphoma. J Biol Chem (2024)32. T Cell Receptor-Directed Bispecific T Cell Engager Targeting MHC-Linked NY-ESO-1 for Tumor Immunotherapy. Biomedicines (2024)33. Zebularine potentiates anti-tumor immunity by inducing tumor immunogenicity and improving antigen processing through cGAS-STING pathway. Commun Biol (2024)34. Artesunate alleviates Sjogren's Syndrome by inhibiting the interferon-alpha signaling in plasmacytoid dendritic cells via TLR-MyD88-IRF7. Biomed Pharmacother (2024)35. Lycorine attenuated proliferation and induced apoptosis on imatinib-resistant K562 cell by inhibiting autophagy. Discov Oncol (2024)36. NOLC1 was identified as a tumor suppressor gene in thyroid cancer and correlated with prognosis by bioinformatics. Am J Cancer Res (2024)37. Golgi dispersal in cancer stem cells promotes chemoresistance of colorectal cancer via the Golgi stress response. Cell Death Dis (2024)38. Class Ⅱ ferroptosis inducers are a novel therapeutic approach for t(4;14)-positive multiple myeloma. Blood Adv (2024)39. A positive feedback loop between PFKP and c-Myc drives head and neck squamous cell carcinoma progression. Mol Cancer (2024)40. CRISPR-Cas9 screening develops an epigenetic and transcriptional gene signature for risk stratification and target prediction in neuroblastoma. Front Cell Dev Biol (2024)41. A novel pulmonary fibrosis NOD/SCID murine model with natural aging. BMC Pulmonary Medicine (2024)42. The lncRNA CADM2-AS1 promotes gastric cancer metastasis by binding with miR-5047 and activating NOTCH4 translation. Frontiers in Pharmacology (2024)43. LMP1 enhances aerobic glycolysis in natural killer/T cell lymphoma. Cell Death Dis (2024)44. Loss of Annexin A1 in macrophages restrains efferocytosis and remodels immune microenvironment in pancreatic cancer by activating the cGAS/STING pathway. Journal for ImmunoTherapy of Cancer (2024)45. ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors. Cancer Research Communications (2024)46. Prolonged Survival of Neutrophils Induced by Tumor-Derived G-CSF/GM-CSF Promotes Immunosuppression and Progression in Laryngeal Squamous Cell Carcinoma. Adv Sci (Weinh) (2024)47. N-(4-methoxyphenyl) quinoline-8-sulfonamide reduces the inflammatory response of fibroblast-like synoviocytes by targeting receptor (calcitonin) activity modifying protein 1 in rheumatoid arthritis. Eur J Pharmacol (2024)48. Construction a novel osteoporosis model in immune-deficient mice with natural ageing. Biochem Biophys Res Commun (2024)49. An antibody cocktail targeting two different CD73 epitopes enhances enzyme inhibition and tumor control. Nat Commun (2024)50. Efficacy and safety of novel multiple-chain DAP-CAR-T cells targeting mesothelin in ovarian cancer and mesothelioma: a single-arm, open-label and first-in …. Genome Med (2024)51. Biological and genetic characterization of a newly established human primary multidrug-resistant distal cholangiocarcinoma cell line, CBC3T-6. Sci Rep (2024)52. CCDC34 maintains stemness phenotype through β-catenin-mediated autophagy and promotes EGFR-TKI resistance in lung adenocarcinoma. Cancer Gene Ther (2024)53. EHD1 promotes breast cancer metastasis through upregulating HIF2a expression via activating mTOR pathway. FASEB J (2024)54. USP7 deubiquitinates KRAS and promotes non-small cell lung cancer. Cell Rep (2024)55. Development of dual aptamers-functionalized c-MET PROTAC degraders for targeted therapy of osteosarcoma. Theranostics (2025)56. ICAT mediates the inhibition of stemness and tumorigenesis in acute myeloid leukemia cells induced by 1,25-(OH)2D3. Oncology research (2025)57. TCL1A in naïve B cells as a therapeutic target for type 1 diabetes. EBioMedicine (2025)58. TMEM45A enhances palbociclib resistance and cellular glycolysis by activating AKT/mTOR signaling pathway in HR+ breast cancer. Cell death discovery (2025)59. Regulating chemoresistance and cancer stemness: the CDH17-YAP pathway in distinct cellular states of lung cancer CTC clusters. Cellular & molecular biology letters (2025)60. The E3 ubiquitin ligase MAEA promotes macrophage phagocytosis and inhibits gastrointestinal cancer progression by mediating PARP1 ubiquitination and degradation. International journal of biological sciences (2025)
Gene Family:	Armadillo like helical domain containing